Bristol-Myers Squibb Company (FRA:BRM)
Germany
· Delayed Price · Currency is EUR | Market Cap | 86.51B |
| Revenue (ttm) | 44.07B |
| Net Income (ttm) | 5.01B |
| Shares Out | n/a |
| EPS (ttm) | 2.47 |
| PE Ratio | 17.25 |
| Forward PE | 7.39 |
| Dividend | 2.26 (5.35%) |
| Ex-Dividend Date | Apr 4, 2025 |
| Volume | 3,734 |
| Average Volume | 2,689 |
| Open | 41.99 |
| Previous Close | 42.25 |
| Day's Range | 41.83 - 42.38 |
| 52-Week Range | 36.42 - 58.79 |
| Beta | n/a |
| RSI | 47.45 |
| Earnings Date | Jul 31, 2025 |
About FRA:BRM
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthrit... [Read more]
News
Why the stock rally fizzled plus, our latest thinking on Goldman and Bristol Myers
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.
Bristol-Myers Squibb Company (BMY) Bernstein 41st Annual Strategic Decisions Conference (Transcript)
Bristol-Myers wins EU nod for Opdivo injectable developed with Halozyme
Bristol-Myers Squibb's Painful Pullback Has Triggered Richer Dividend Story - Upgrade To Buy
Bristol Myers Squibb to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11, 2025. The company will take part...
Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo (nivolumab) Across Multiple Solid Tumor Indications
Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved a new Opdivo (nivolumab) formulation associated with a new route of administration (subcutaneous use [SC...
Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications
Opdivo is the first and only PD-1 inhibitor approved for subcutaneous (SC) use in the European Union Approval is based on results from the Phase 3 CheckMate -67T clinical trial which demonstrated noni...
Bristol-Myers Squibb: This Undervalued Dog Needs An Option Collar
Bristol-Myers: Among The Cheapest Pharma Names, Now Yielding Above 5%
Bristol-Myers Squibb At ASCO 2025: A Resilient Play Amid Market Turbulence
Bristol Myers Squibb to Present Data at ASCO 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline
Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its oncology portfolio and pipeline at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting to be held ...
Bristol Myers Squibb to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline
Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its oncology portfolio and pipeline at the 2025 American Society of Clinical Oncology (ASCO ®) Annual Meeting to be h...
Major US stock indices close today lower as yields rise
The major US stock indices a closing lower on the day. The Dow industrial average was the worst performer with a decline of -1.91%. The top 10 decliners for the day: UnitedHealth Group (UNH): −5.78% N...
Bristol Myers gets EU nod for Opdivo combo in lung cancer treatment
Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small Cell Lung Cancer with PD-L1 Expression ≥1%
Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved the perioperative regimen of neoadjuvant Opdivo (nivolumab) and chemotherapy followed by surgery and adj...
EXCLUSIVE: FDA Clears Lantern Pharma's Planned Phase 1b/2 Trial of LP-184 In Treatment-Resistant Lung Cancer Patients
The U.S. Food and Drug Administration (FDA) on Monday cleared the amendment to Lantern Pharma Inc.’s (NASDAQ: LTRN) Investigational New Drug (IND) application for the Phase 1b/2 trial of LP-184 in a ...
Bristol-Myers Squibb (BMY) and Sanofi Settle Plavix Lawsuit for $700M
Bristol-Myers Squibb (BMY) and Sanofi Settle Plavix Lawsuit for $700M
Bristol-Myers, Sanofi ink $700M settlement with Hawaii to resolve Plavix lawsuit
A Look Into Bristol-Myers Squibb Inc's Price Over Earnings
Looking into the current session, Bristol-Myers Squibb Inc. (NYSE: BMY) shares are trading at $47.05, after a 1.20% decrease. Over the past month, the stock decreased by 6.76% , but over the past yea...
2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb
Acquisition by Bristol Myers Squibb on track to close in the second quarter of 2025: HSR waiting period expired on May 2, 2025; tender offer expected to expire on May 13, 2025 Abecma generated $59 mil...
Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer
Bristol Myers Squibb (NYSE: BMY) today announced the appointment of Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer, effective immediately. Gallman succeeds Sandra (...
FDA Pushes Potential Approval For Cytokinetics' Experimental Heart Drug By Three Months
The U.S. Food and Drug Administration (FDA) on Thursday extended the Prescription Drug User Fee Act (PDUFA) action date for the New Drug Application (NDA) for Cytokinetics Inc's (NASDAQ: CYTK) aficam...
Bristol-Myers Squibb (BMY) Revenue Beats, EPS Misses Estimates
Bristol-Myers Squibb (BMY) Revenue Beats, EPS Misses Estimates
Trump pharma tariffs would raise U.S. drug costs by $51 billion annually, report finds
Pharmaceutical Research and Manufacturers of America includes Amgen, Bristol Myers Squibb, Eli Lilly, and Pfizer, among others.